Natriuretic Peptide-Guided Therapy in Chronic Heart Failure: A Meta-Analysis of 2,686 Patients in 12 Randomized Trials

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Savarese, Gianluigi ^a   Trimarco, Bruno ^a   Dellegrottaglie, Santo ^a,b   Prastaro, Maria ^a   Gambardella, Francesco ^a   Rengo, Giuseppe ^a   Leosco, Dario ^a   Perrone Filardi, Pasquale ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Division of Cardiology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; NATRIURETIC FACTOR; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; HEART FAILURE; HOSPITALIZATION; HUMAN; META ANALYSIS; MORTALITY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT RESPONSE; AGE; AGED; CHRONIC DISEASE; FEMALE; MALE; MIDDLE AGED; RISK; TREATMENT OUTCOME;

AGE FACTORS; AGED; CHRONIC DISEASE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84874622727     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058287     Document Type: Article

References (46)

1. Fang J, Mensah GA, Croft JB, Keenan NL, (2008) Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 52: 428-434.
2. Authors/Task Force Members, McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, et al. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14: 803-869.
3. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ, (2001) More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 3: 315-322.
4. Schou M, Gustafsson F, Videbaek L, Tuxen C, Keller N, et al. (2012) Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar). Eur Heart J. doi:10.1093/eurheartj/ehs235.
5. Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, et al. (2005) Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 26: 1653-1659.
6. Powell LH, Calvin JE Jr, Richardson D, Janssen I, Mendes de Leon CF, et al. (2010) Self-management counseling in patients with heart failure: the heart failure adherence and retention randomized behavioral trial. JAMA 304: 1331-1338.
7. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, et al. (2004) Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma Nterminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 90: 297-303.
8. White M, Rouleau JL, Afzal R, Floras J, Yusuf S, et al. (2009) Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker. Ther Adv Cardiovasc Dis 3: 113-121.
9. Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, et al. (2009) Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 119: 2471-2479.
10. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, et al. (2004) Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110: 1780-1786.
11. Berry C, Murphy NF, De Vito G, Galloway S, Seed A, et al. (2007) Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a betablocker. Eur J Heart Fail 9: 429-434.
12. Adams KF Jr, Felker GM, Fraij G, Patterson JH, O'Connor CM, (2010) Biomarker guided therapy for heart failure: focus on natriuretic peptides. Heart Fail Rev 15: 351-370.
13. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, et al. (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355: 1126-1130.
14. Beck-da-Silva L, de Bold A, Fraser M, Williams K, Haddad H, (2005) BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure. Congest Heart Fail 11: 248-253.
15. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, et al. (2007) Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49: 1733-1739.
16. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, et al. (2009) BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301: 383-392.
17. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, et al. (2009) N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 55: 53-60.
18. Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, et al. (2010) Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure-SIGNAL-HF (Swedish Intervention study-Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail 12: 1300-1308.
19. Eurlings LW, van Pol PE, Kok WE, van Wijk S, Lodewijks-van der Bolt C, et al. (2010) Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol 56: 2090-2100.
20. Anguita M, Esteban F, Castillo JC, Mazuelos F, López-Granados A, et al. (2010) Usefulness of brain natriuretic peptide levels, as compared with usual clinical control, for the treatment monitoring of patients with heart failure. Med Clin. (Barc) 135: 435-440.
21. Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, et al. (2010) N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 55: 645-653.
22. Shah MR, Califf RM, Nohria A, Bhapkar M, Bowers M, et al. (2011) The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail 17: 613-621.
23. Karlström P, Alehagen U, Boman K, (2011) Dahlström U; UPSTEP-study group (2011) Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail 13: 1096-1103.
24. Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, et al. (2011) Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 58: 1881-1889.
25. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM, (2009) Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 158: 422-430.
26. Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H, (2010) B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med 170: 507-514.
27. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, et al. (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119: 1977-2016.
28. Moher D, Liberati A, Tetzlaff J, (2009) Altman DG; PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62: 1006-1012.
29. Costanzo P, Perrone-Filardi P, Petretta M, Marciano C, Vassallo E, et al. (2009) Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients. J Hypertens 27: 1136-1151.
30. Savarese G, Musella F, Volpe M, Paneni F, Perrone-Filardi P (2012) Effects of atorvastatin and rosuvastatin on renal function: A meta-analysis. Int J Cardiol. doi:10.1016/j.ijcard.2012.05.010.
31. Savarese G, Paolillo S, Costanzo P, D'Amore C, Cecere M, et al. (2012) Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? J Am Coll Cardiol 60: 1192-1201.
32. Detsky A, Naylor C, O'Rourke K, McGeer A, L'Abbé K, (1992) Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol 45: 255-265.
33. Sharp S 1, Sterne J (1998) Meta-analysis. STB Reprints 7: 100-108.
34. Whitehead A (2002) Meta-analysis of Controlled Clinical Trials. Chichester, England: John Wiley & Sons Inc.
35. Davies HT, Crombie IK, Tavakoli M, (1998) When can odds ratios mislead? BMJ 316: 989-991.
36. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A, (2007) Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26: 53-77.
37. Sharp SJ, (1998) Meta-analysis regression. STB 42: 16-22.
38. Thompson SG, Sharp SJ, (1999) Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 18: 2693-2708.
39. Tobias A, (1999) Assessing the influence of a single study in meta-analysis. STB 47: 15-17.
40. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L, (2006) Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680.
41. Higgins JP, Deeks JJ (2011) Chapter 7: selecting studies and collecting data. In: Higgins JP, Green S, ed. Cochrane handbook for systematic reviews of interventions (Version 5.1.0). Available on http://www.cochrane-handbook.org/.
42. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M, (1998) Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135: 825-832.
43. Prastaro M, Paolillo S, Savarese G, Dellegrottaglie S, Scala O, et al. (2011) N-terminal pro-b-type natriuretic peptide and left atrial function in patients with congestive heart failure and severely reduced ejection fraction. Eur J Echocardiogr 12: 506-513.
44. Metra M, Zacà V, Parati G, Agostoni P, Bonadies M, et al. (2011) Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. J Cardiovasc Med 12: 76-84.
45. Hildebrandt P, Collinson PO, Doughty RN, Fuat A, Gaze DC, et al. (2010) Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. Eur Heart J 31: 1881-1889.
46. Steiner J, Guglin M, (2008) BNP or NTproBNP? A clinician's perspective. Int J Cardiol 129: 5-14.